BMJ Open
September 22, 2026
Anna Kristina Eigenbrodt, Poul P Laigaard, Melika Hassani et al.
Recovery of consciousness after brain injury remains a major challenge in the intensive care unit (ICU), and pharmacological treatments that directly promote awakening from coma and other disorders of consciousness (DoC) are lacking. We hypothesise that simultaneously targeting the two core components of consciousness by pharmacological means-arousal with apomorphine and awareness with...
International Journal of Innovative Technologies in Social Science
September 21, 2026
Mateusz Gawin, Emilia Koziara, Mateusz Gadzina et al.
Major depressive disorder (MDD) is one of the leading causes of disability worldwide. A substantial proportion of patients fail to achieve remission through standard monoaminergic therapies, meeting the clinical criteria for treatment-resistant depression (TRD). TRD is associated with significant clinical morbidity and a profound economic burden on healthcare systems. This review evaluates the...
British Journal of Clinical Pharmacology
September 21, 2026
Anna Signor, Stefano Comai, Gianfranco Pasut et al.
AIMS: This study aimed to evaluate the safety, tolerability and pharmacokinetics of a novel oral modified-release psilocybin formulation (REL-P11) in normal-weight and overweight/obese healthy adults and to assess its suitability for controlled, subperceptual exposure, in light of emerging evidence supporting serotonergic modulation in metabolic disorders. METHODS: Simulation-based modelling...
Pharmaceuticals
September 21, 2026
Naama Levy‐Cooperman, Edward M. Sellers, Paul Glue et al.
Background/Objectives: Psilocybin shows therapeutic promise for several psychiatric disorders, but the acute perceptual and cognitive alterations produced by conventional doses (10–25 mg) require in-clinic supervision, which limits scalability. Whether the therapeutically relevant pharmacology of psilocybin can be safely separated from its hallucinogenic activity remains unresolved. To address...
Mini-Reviews in Medicinal Chemistry
September 18, 2026
Fatemeh Abolhasani, Hojjat Rezaiezadeh, Mohammad Amin Langarizadeh et al.
Psilocybin, a compound found in certain species of Psilocybe mushrooms, shows potential as a treatment for various psychiatric conditions. In the past decade, a growing body of evidence has shown the effectiveness of psilocybin in treating conditions, such as treatment-resistant depression, generalized anxiety disorder, post-traumatic stress disorder, and substance use disorders. This review...
Journal of Pain and Symptom Management
September 18, 2026
Megan Miller, Molly Meyers, Candace Oglesby-Adepoju et al.
Psilocybin-assisted therapy (PAT) shows promise for alleviating psychological and existential distress among people with cancer; however, research is limited by homogeneous samples, raising concerns about generalizability and equity. To explore perceptions and attitudes of PAT among a subset of people with cancer who have been underrepresented in research. A qualitative descriptive study was...
Molecular Psychiatry
September 17, 2026
James J Gattuso, Bilgenur Bezcioglu, Jenna Hendey et al.
Obsessive-compulsive disorder (OCD) remains difficult to treat, and evidence indicates that social dysfunction, common across obsessive-compulsive and related disorders, is an under-recognized clinical burden. SAPAP3 knockout (KO) mice, a well-established model of compulsive behavior, exhibit social abnormalities, suggesting broader disruptions in circuits relevant to social cognition. Here, we...
npj Mental Health Research
September 16, 2026
Orly Lipsitz, Ryan M Brudner, Zoe Doyle et al.
Cluster B personality disorders (PDs) are highly comorbid with depression and are associated with attenuated antidepressant response. No clinical trials to date have reported on psilocybin-assisted psychotherapy (PAP) in comorbid treatment-resistant depression (TRD) and PDs. This is the first clinical trial to describe a subgroup of ten participants with a comorbid PD ( n = 9 cluster B; n = 1...
Frontiers in Psychiatry
September 15, 2026
Serena Chiara Civardi, Filippo Besana, Federico Durbano et al.
Background Treatment-resistant depression (TRD) is a major clinical challenge, with many patients failing to respond to conventional antidepressants. Psychedelic compounds such as psilocybin and ayahuasca have recently gained attention as potential rapid-acting therapies. Beyond their neurobiological effects, methodological, ethical, and real-world applicability concerns are critical for...
Chinese medical journal
September 15, 2026
Yingjie Du, Xiangting Zhao, Quan Chen et al.
Psilocybin facilitates fear extinction in rodents, but its clinical utility is hampered by 5-hydroxytryptamine (5-HT) 2A-receptor-mediated hallucinogenic effects. This study aimed to explore whether 5-HT2A receptor is obligatory for psilocybin's fear extinction and neuroplasticity effect. Male C57BL/6J mice underwent auditory-cue fear conditioning. Ketanserin (5-HT2A/2C antagonist) or MDL100907...